drugset / Trial / NCT03223272

Mechanisms of Refractory Hypertension (Reserpine)

NCT03223272

Phase 2 Completed 7 enrolled University of Alabama at Birmingham
NaSingle-groupOpen-labelTreatment

Summary

The study is deigned to determine if refractory hypertension is attributable to heightened sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic agent, in patients failing other classes of antihypertensive agents.

Timeline

Start
2015-07-23
Primary completion
2020-01-31
Completion
2020-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject reserpine Small molecule 0.1 mg Oral